BTIG Maintains Buy on Organogenesis Hldgs, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has maintained a 'Buy' rating on Organogenesis Hldgs (NASDAQ:ORGO) but lowered the price target from $10 to $4.

August 10, 2023 | 7:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Organogenesis Hldgs' price target has been lowered from $10 to $4 by BTIG, though the 'Buy' rating is maintained.
The lowering of the price target by BTIG indicates a potential decrease in the stock's value. However, the maintained 'Buy' rating suggests that the stock is still expected to perform well in the long term. This could lead to short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100